Home > News > Midatech nanoparticles heading for the clinic in Q1 2008
May 14th, 2007
Midatech nanoparticles heading for the clinic in Q1 2008
Midatech, the UK group exploring the therapeutic and diagnostic applications of nanoparticles as drug delivery vehicles, scaffolds for synthetic vaccines or antibiotics and non-invasive imaging agents, aims to put its first product into clinical trials in the first quarter of 2008.
This will be multivalent antibiotics delivered on nanoparticles, said Midatech's Storme Thornicroft. The group's listed pipeline includes a project coded MTL 201 that involves antibiotics for the treatment of the 'superbug' methicillin-resistant Staphylococcus aureus (MRSA).
Aptasensors Help Detection of Cancer Protein Marker March 9th, 2014
Nano Labs Shareholder Update March 8th, 2014
MANA Research Highlight: Smart nanofibers to treat kidney failure March 6th, 2014
Harris & Harris Group, Inc. Establishes and Invests $350,001 in ProMuc, Inc. March 6th, 2014
A bright future for optoelectronics: A diode made from a 2D material facilitates novel solar cells March 10th, 2014
Scientists build thinnest-possible LEDs to be stronger, more energy efficient March 10th, 2014
Two-dimensional material shows promise for optoelectronics: Team creates LEDs, photovoltaic cells, and light detectors using novel 1-molecule-thick material March 10th, 2014
Toxicity of Commonly-Used Nanoparticles on Human Body Studied in Iran March 9th, 2014